Skip to main content

Table 4 GEE analysis of the interaction of group and time on EMG_NCV indices

From: Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial

Variable   B Std. error Wald chi-square P value
Ulnar NCV G2/1 * T9/0 3.222 3.5649 .817 .366
G2/1 * T3/0 5.000 3.3491 2.229 .135
G2/1 * T9/3 − 1.778 1.4577 1.487 .223
Ulnar Amp G2/1 * T9/0 .333 .3128 1.136 .287
G2/1 * T3/0 − .117 .4228 .076 .783
G2/1 * T9/3 .450 .3670 1.503 .220
Median NCV G2/1 * T9/0 .500 2.6094 .037 .848
G2/1 * T3/0 2.889 3.2224 .804 .370
G2/1 * T9/3 − 2.389 1.9513 1.499 .221
Median Amp G2/1 * T9/0 − .222 .2185 1.034 .309
G2/1 * T3/0 .100 .3142 .101 .750
G2/1 * T9/3 − .322 .3191 1.019 .313
Tibial NCV G2/1 * T9/0 .056 2.6936 .000 .984
G2/1 * T3/0 1.889 3.3171 .324 .569
G2/1 * T9/3 − 1.833 2.3878 .589 .443
Tibial Amp G2/1 * T9/0 − .244 .1706 2.052 .152
G2/1 * T3/0 − .150 .2017 .553 .457
G2/1 * T9/3 − .094 .1605 .346 .556
Proneal NCV G2/1 * T9/0 .083 2.7807 .001 .976
G2/1 * T3/0 3.056 3.7217 .674 .412
G2/1 * T9/3 − 2.972 2.1796 1.860 .173
Proneal Amp G2/1 * T9/0 − .067 .2034 .107 .743
G2/1 * T3/0 .022 .2310 .009 .923
G2/1 * T9/3 − .089 .1557 .326 .568
Symptoms Group 2/1 .138 .19 .54 .386
time .061 .01 55.99 <.001
G2*T9/0 − .003 .01 .05 .352
  1. G2/1: Group 2 compared to group 1
  2. T9/0: 9th months compared to start time
  3. T3/0: 3rd months compared to start time
  4. T9/3: 9th months compared to 3rd months
  5. NCV nerve conduction velocity, Amp amplitude